Cancer Res Treat.  2019 Oct;51(4):1600-1611. 10.4143/crt.2018.426.

Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea

• Mai TT
• Choi JH
• Lee MK
• Chang YJ
• Jung SY
• Cho H
• Lee ES

• KMID: 2460608
• DOI: http://doi.org/10.4143/crt.2018.426

Abstract

PURPOSE
We aimed to evaluate health-related quality of life (HRQOL) at 1-year post-diagnosis in breast cancer (BC) patients and its association with overall survival using data from the National Cancer Center Hospital.
MATERIALS AND METHODS
Data of a BC cohort were first obtained between 2004 and 2006 and followed up. HRQOL was assessed using EORTC QLQ-C30 and BC specific module QLQ-BR23 few days after diagnosis and 1 year after that. We examined and compared the difference in the two HRQOL scores measured for each patient by the patient's current survival status. The Cox proportional hazards model was fitted to evaluate the impact of HRQOL on survival, with adjustment for baseline HRQOL and other factors.
RESULTS
Of 299 enrolled patients, 206 responded at 1-year post-diagnosis (80.6%) and were followed up for 11.6 years on average. At 1-year post-diagnosis, survivors had better HRQOL scores than those who died, although their health status was similar at baseline. Survivors reported significant increase 1 year after diagnosis in global health status and emotional scales. Between the groups, functional scales such as physical, role, and emotional were significantly different. Functional scales, including physical (adjusted hazard ratio [aHR], 0.70), role (aHR, 0.68), emotional (aHR, 0.72), and symptom scales, including fatigue (aHR, 1.34), dyspnea (aHR, 1.29), appetite loss (aHR, 1.24) were significantly associated with overall survival. Patients who were less worried about future health had favorable survival(aHR, 0.83).
CONCLUSION
Besides treatment-related symptoms, non-medical aspects at 1-year post-diagnosis, including functional well-being and future perspective, are predictive of long-term survival. Intervention to enhance physical, role, and emotional support for women soon after their BC diagnosis might help to improve disease survival outcomes afterwards.

Keyword

Breast neoplasms; Quality of life; Overall survival

MeSH Terms

Appetite
Breast Neoplasms*
Breast*
Cohort Studies*
Diagnosis
Dyspnea
Fatigue
Female
Global Health
Humans
Korea*
Proportional Hazards Models
Prospective Studies*
Quality of Life*
Survivors
Weights and Measures

Figure

• 

  Fig. 1. Enrollment of cohort, health-related quality of life (QOL) assessments and follow-up period. BC, breast cancer; NCC, National Cancer Center; F/U, follow-up.

• 

  Fig. 2. Health-related quality of life (QOL) measured by QLQ-C30 functional scale after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the QOL mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.

• 

  Fig. 3. Health-related quality of life (QOL) measured by QLQ-C30 symptom scale after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the quality of life (QOL) mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.

• 

  Fig. 4. Health-related quality of life (QOL) measured by QLQ-BR23 after diagnosis (baseline) and at 1-year post-diagnosis (1 year). Blue color indicates the QOL mean scores and 95% confidence intervals for survivors. Red color indicates QOL mean scores and 95% confidence intervals for deaths. p-values were obtained using the Kruskal-Wallis test to compare QOL scores measured at 1-year post-diagnosis between survivors and deaths.

Reference

References

1. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008; 26:1355–63.

2. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008; 27:32.

3. Hahn EA, Cella D, Chassany O, Fairclough DL, Wong GY, Hays RD, et al. Precision of health-related quality-of-life data compared with other clinical measures. Mayo Clin Proc. 2007; 82:1244–54.

4. Sprangers MA. Disregarding clinical trial-based patient-reported outcomes is unwarranted: five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol. 2010; 49:155–63.

5. Staren ED, Gupta D, Braun DP. The prognostic role of quality of life assessment in breast cancer. Breast J. 2011; 17:571–8.

6. Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennelart H, Tredaniel J, et al. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. Eur J Cancer. 2016; 52:120–8.

7. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? II. Experiences from the treatment of cancer. Eur J Cancer Care (Engl). 1996; 5:168–75.

8. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? I. Meaning, purposes and controversies. Eur J Cancer Care (Engl). 1996; 5:159–67.

9. Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016; 14:52.

10. Gupta D, Granick J, Grutsch JF, Lis CG. The prognostic association of health-related quality of life scores with survival in breast cancer. Support Care Cancer. 2007; 15:387–93.

11. Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Pluzanska A, Ottoson S, Mouridsen H, et al. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer. 2003; 39:1370–6.

12. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987; 317:1490–5.

13. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol. 1992; 10:1833–8.

14. Coates AS, Hurny C, Peterson HF, Bernhard J, CastiglioneGertsch M, Gelber RD, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol. 2000; 18:3768–74.

15. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997; 6:151–8.

16. Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol. 2004; 22:3381–8.

17. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000; 36:1498–506.

18. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007; 105:209–19.

19. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu-Lehtinen P. Baseline psychosocial predictors of survival in localised breast cancer. Br J Cancer. 2006; 94:1245–52.

20. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009; 10:865–71.

21. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004; 40:1021–30.

22. Lee ES, Lee MK, Kim SH, Ro JS, Kang HS, Kim SW, et al. Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study. Ann Surg. 2011; 253:101–8.

23. Lee MK, Park S, Lee ES, Ro J, Kang HS, Shin KH, et al. Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study. Support Care Cancer. 2011; 19:1379–92.

24. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85:365–76.

25. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996; 14:2756–68.

26. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst. 2011; 103:178–231.

27. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004; 13:863–8.

28. Yun YH, Bae SH, Kang IO, Shin KH, Lee R, Kwon SI, et al. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer. 2004; 12:441–5.

29. Fayers P, Artonson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer;2001.

30. Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer Suppl. 1999; 12:132–7.

31. Gralla RJ, Griesinger F. Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol. 2007; 2 Suppl 2:S51–8.

32. Gupta D, Braun DP, Staren ED. Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl). 2012; 21:614–22.

33. Zhao W, Wu Z, Chen J, Jia H, Huang Z, Chen M, et al. Survival prediction of anxious emotion in advanced cancer patients receiving palliative care. Psychooncology. 2017; 26:1463–9.

34. Kim S, Kwon S. The effect of extension of benefit coverage for cancer patients on health care utilization across different income groups in South Korea. Int J Health Care Finance Econ. 2014; 14:161–77.

35. Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, et al. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol. 2016; 27:2224–9.

36. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016; 34:980–6.

37. Chino F, Peppercorn J, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP, et al. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist. 2014; 19:414–20.

38. Kang D, Cho J, Kim IR, Kim MK, Kim WS, Kim SJ. Health-related quality of life in non-hodgkin lymphoma survivors: a prospective cohort study. Cancer Res Treat. 2018; 50:1051–63.

39. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013; 18:381–90.